ArticleClinical ophthalmology (Auckland, N.Z.)2025
Predictive Factors for Macular Atrophy in Patients with Treated Myopic Macular Neovascularization.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Macular atrophy represents an end-stage of myopic maculopathy. This study aims to identify predictive factors for atrophy growth in patients with treated myopic macular neovascularization (mMNV). Methods: Retrospective study including 98 eyes from 83 patients registered in the national database of retinal diseases and followed and treated for mMNV for at least 2-years at our tertiary center. Our primary outcomes were the increase in the chorioretinal atrophic area (CRA) and final best corrected visual acuity (fBCVA). Results: Most patients (n=55, 56.1%) successfully stopped treatment after 3+pro re nata (3+PRN) (mean 6.8±5.3 intravitreal injections, IVI), while 27 patients (27.6%) required uninterrupted treat and extend (T&E) regimen (mean 27±15.46 IVI). BCVA improved from 47.18±23.06 to 58.66±21.27 ETDRS letters after mMNV treatment, over a mean of 6.04±4.1 years [2-15]. There was a 16.9% larger final mean CRA and a mean growth of 0.48±1.17mm Conclusion: Macular atrophy after mMNV leads to irreversible visual loss. The baseline atrophic area predicts final macular atrophy. Initial SCT and the implemented treatment regimen (especially with a higher number of IVI) influence atrophy growth, although not significant in the multivariable model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.